| Identification | Back Directory | [Name]
Pyrimido[2,1-f]purine-2,4(1H,3H)-dione, 6,7,8,9-tetrahydro-9-[2-(1H-indol-3-yl)ethyl]-1,3-dimethyl- | [CAS]
955121-65-0 | [Synonyms]
PSB-KD107
Pyrimido[2,1-f]purine-2,4(1H,3H)-dione, 6,7,8,9-tetrahydro-9-[2-(1H-indol-3-yl)ethyl]-1,3-dimethyl- | [Molecular Formula]
C20H22N6O2 | [MOL File]
955121-65-0.mol | [Molecular Weight]
378.43 |
| Chemical Properties | Back Directory | [Melting point ]
230-232 °C(Solv: 1-propanol (71-23-8)) | [Boiling point ]
661.5±65.0 °C(Predicted) | [density ]
1.47±0.1 g/cm3(Predicted) | [solubility ]
DMF: 2 mg/ml; DMSO: 2 mg/ml; DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml | [form ]
A crystalline solid | [pka]
17.31±0.30(Predicted) |
| Hazard Information | Back Directory | [Description]
PSB-KD107 is an agonist of the Cannabinoid-Activated Orphan G?Protein-Coupled Receptor GPR18. PSB-KD107 displayed significantly higher potency and efficacy than THC, determined in a GPR18-dependent β-arrestin recruitment assay, and were found to be selective versus the CB-sensitive receptors CB1, CB2, and GPR55. | [Uses]
PSB-KD107 is an agonist of the cannabinoid activated orphan G-protein-coupled receptor GPR18, and PSB-KD107 has anti-inflammatory activity. PSB-KD107 can be used in the study of Duchenne muscular dystrophy[1]. | [References]
[1] Dort J, et al. Gpr18 agonist dampens inflammation, enhances myogenesis, and restores muscle function in models of Duchenne muscular dystrophy. Front Cell Dev Biol. 2023 Aug 14;11:1187253. DOI:10.3389/fcell.2023.1187253 |
|
|